Evidence map›Paper›PMID 42077441›Full record

ArticleFrontiers in endocrinology2026

Overweight/obesity accelerates proteinuria progression in type 2 diabetes post-COVID-19: a comparison with a pre-pandemic uninfected cohort.

Jiajun Wu, Liping Gu, Qin Zhen, Jiaying Yang, Yizhe Wang, Yongcheng Zhang, Yizhen Chen, Fang Liu, Xiaoying Ding, Yufan Wang and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiajun Wu *Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liping Gu *Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qin Zhen *Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiaying YangDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yizhe WangDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yongcheng ZhangDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yizhen ChenDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fang LiuDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoying DingDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yufan WangDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Na LiDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To assess whether overweight/obesity accelerates proteinuria progression in patients with type 2 diabetes mellitus (T2DM) after coronavirus disease 2019 (COVID-19) infection. Methods: This retrospective study included 688 patients with T2DM confirmed to have COVID-19 infection and 502 pre-pandemic uninfected patients with T2DM for comparative analysis. Participants were categorized based on body mass index (BMI) into normal weight (BMI <24 kg/m Results: Of the 688 infected participants, 8.5% experienced proteinuria progression. Within the infected cohort, the incidence of progression in the overweight/obese group (10.8%) was significantly higher than in the normal weight group (4.9%, P = 0.012). Critically, the incidence of progression in the infected overweight/obese group (10.8%) was also significantly higher than that in their uninfected overweight/obese counterparts (5.8%, P = 0.016). In the COVID-19 infection cohort, overweight/obese was associated with a 2.682-fold higher risk of proteinuria progression after COVID-19 infection compared to the normal weight group (OR, 2.682; 95%CI, 1.273-5.648; P = 0.009). Furthermore, every 1 kg/m Conclusions: Overweight/obese accelerates proteinuria progression in patients with T2DM following COVID-19 infection. Therefore, emphasizing the importance of obesity management is crucial to prevent renal complications in patients with T2DM after COVID-19.

Indexed as

COVID-19Diabetes Mellitus, Type 2ObesityOverweightProteinuriaAgedBody Mass IndexCohort StudiesDisease ProgressionFemaleHumansMaleMiddle AgedPandemicsRetrospective StudiesSARS-CoV-2COVID-19overweight/obesityproteinuria progressionretrospective studytype 2 diabetes mellitus

Identifiers

PMID42077441
PMCPMC13132767

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.